Key statistics
52-week range
Short selling activityProvided by S&P Global Market Intelligence
| Open | 0.8445 |
|---|---|
| High | 0.8937 |
| Low | 0.8445 |
| Bid | 0.8403 |
| Offer | 0.8937 |
| Previous close | 0.8295 |
| Average volume | 86.19k |
|---|---|
| Shares outstanding | 7.17m |
| Free float | 5.50m |
| P/E (TTM) | -- |
| Market cap | 5.95m USD |
| EPS (TTM) | -9.62 USD |
Data delayed at least 15 minutes, as of Feb 11 2026 14:39 GMT.
More ▼
Announcements
- Calidi Biotherapeutics Provides Corporate Update and Key Value Drivers for 2026
- Calidi Biotherapeutics Announces Exclusive Live Investor Webinar and Q&A Session on November 19, 2025
- Calidi Biotherapeutics Reports Third Quarter 2025 Financial Results and Recent Operational Highlights
- Calidi Biotherapeutics Presents New Data on its Therapeutic Lead, CLD-401, at the 2025 SITC Annual Meeting and Holds Its First Investor Day at SITC
- Calidi Biotherapeutics Announces Investor Event to be Held on Friday, November 7th at the 2025 SITC Annual Meeting
- Calidi Biotherapeutics Announces New Data to be Presented on its Therapeutic Lead, CLD-401, at the 2025 SITC Annual Meeting
- Calidi Biotherapeutics Announces Establishment of Scientific Advisory Board to Support Development of CLD-401 and Advance its RedTail Platform for the Systemic Delivery of Targeted Genetic Medicine
- Calidi Biotherapeutics to Present at the second annual Oncology Venture, Innovation, and Partnering Summit in Boston
- Calidi Biotherapeutics to Present at the H.C. Wainwright 27th Annual Global Investment Conference
- Calidi Biotherapeutics Announces Closing of $6.9 Million Underwritten Public Offering and Full Exercise of Underwriters’ Over-Allotment Option
More ▼
